Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
Annals of Internal Medicine|June 21, 2021
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized TrialMichael Szarek, Deepak L Bhatt, Ph Gabriel Steg, et al.
JACC. Heart Failure|August 9, 2023
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHFBertram Pitt, Deepak L Bhatt, Michael Szarek, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseDeepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Pageof 9